Application | Comment | Organism |
---|---|---|
medicine | controlling GSK-3beta signaling in bone cells is a strategy for preventing glucocorticoid-induced osteopenia | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
6-bromoindirubin-3'-oxim | - |
Mus musculus |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
cytosol | - |
Mus musculus | 5829 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
MC3T3-E1 cell | - |
Mus musculus | - |
osteoblast | - |
Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + beta-catenin | - |
Mus musculus | ADP + phosphorylated beta-catenin | - |
? |
Synonyms | Comment | Organism |
---|---|---|
glycogen synthase kinase-3beta | - |
Mus musculus |
GSK-3beta | - |
Mus musculus |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
ATP | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
malfunction | inhibition of GSK-3beta abrogates glucocorticoid-induced bone loss by increasing beta-catenin- and Runx2-mediated osteoblast differentiation | Mus musculus |